The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development
Open accessAbstract
Indoleamine 2,3-dioxygenase (IDO) enzyme inhibitors have entered clinical trials for cancer treatment based on preclinical studies, indicating that they can defeat immune escape and broadly enhance other therapeutic modalities. However, clear genetic evidence of the impact of IDO on tumorigenesis in physiologic models of primary or metastatic disease is lacking. Investigating the impact of Ido1 gene disruption in mouse models of oncogenic KRAS-induced lung carcinoma and breast carcinoma–derived pulmonary metastasis, we have found that IDO deficiency resulted in reduced lung tumor burden and improved survival in both models. Micro-computed tomographic (CT) imaging further revealed that the density of the underlying pulmonary blood vessels was significantly reduced in Ido1-nullizygous mice. During lung tumor and metastasis outgrowth, interleukin (IL)-6 induction was greatly attenuated in conjunction with the loss of IDO. Biologically, this resulted in a consequential impairment of protumorigenic myeloid-derived suppressor cells (MDSC), as restoration of IL-6 recovered both MDSC suppressor function and metastasis susceptibility in Ido1-nullizygous mice. Together, our findings define IDO as a prototypical integrative modifier that bridges inflammation, vascularization, and immune escape to license primary and metastatic tumor outgrowth. Significance: This study provides preclinical, genetic proof-of-concept that the immunoregulatory enzyme IDO contributes to autochthonous carcinoma progression and to the creation of a metastatic niche. IDO deficiency in vivo negatively impacted both vascularization and IL-6–dependent, MDSC-driven immune escape, establishing IDO as an overarching factor directing the establishment of a protumorigenic environment. Cancer Discov; 2(8); 722–35. ©2012 AACR. Read the Commentary on this article by Novitskiy et al., p. 673. This article is highlighted in the In This Issue feature, p. 653.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current Protocols in Immunology
(2018) · Current Protocols in Immunology · doi:10.1002/(issn)1934-368x · Cited by 3,566
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272 · cited 1×
“In contrast, IL-6 may exert a counter-regulatory feedback effect by inducing SOCS3 (suppressor of cytokine signaling 3), which not only attenuates IL-6 signaling (49) but also limits IDO transcription and IDO enzyme stability (50, 51).”
BackgroundPrevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I., Conway, S. J., Marshall, B., Brown, C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,585
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“25)] activity is substantially elevated within the tumor cells themselves (8, 33), enabling the malignancy to preemptively shape its surroundings through intrinsic tryptophan catabolism.”
BackgroundAn endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
Self-citationTumor Self-Seeding by Circulating Cancer Cells
Kim, M.-Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H.-F., Norton, L., & Massagué, J. (2009) · Cell · doi:10.1016/j.cell.2009.11.025 · Cited by 1,335
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064
The role of IL-6 and STAT3 in inflammation and cancer
Hodge, D. R., Hurt, E. M., & Farrar, W. L. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.016 · Cited by 950
Pulaski, B. A., & Ostrand‐Rosenberg, S. (2000) · Current Protocols in Immunology · doi:10.1002/0471142735.im2002s39 · Cited by 912
Self-citationCurrent Protocols in Immunology
(2001) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471142735 · Cited by 785
Prostaglandin E2 Promotes Tumor Progression by Inducing Myeloid-Derived Suppressor Cells
Sinha, P., Clements, V. K., Fulton, A. M., & Ostrand-Rosenberg, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4174 · Cited by 755
Self-citationDiNatale, B. C., Murray, I. A., Schroeder, J. C., Flaveny, C. A., Lahoti, T. S., Laurenzana, E. M., Omiecinski, C. J., & Perdew, G. H. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq024 · Cited by 634
Bunt, S. K., Yang, L., Sinha, P., Clements, V. K., Leips, J., & Ostrand-Rosenberg, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2354 · Cited by 633
Self-citationHou, D.-Y., Muller, A. J., Sharma, M. D., DuHadaway, J., Banerjee, T., Johnson, M., Mellor, A. L., Prendergast, G. C., & Munn, D. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2925 · Cited by 586
Self-citationInflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage
Grivennikov, S. I., & Karin, M. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.140145 · Cited by 560 · cited 1×
“Numerous other studies indicate that IL-6 can also contribute to tumor promotion by supporting angiogenesis and neovascularization of tumors (42, 43).”
BackgroundInflammation Induces Myeloid-Derived Suppressor Cells that Facilitate Tumor Progression
Bunt, S. K., Sinha, P., Clements, V. K., Leips, J., & Ostrand-Rosenberg, S. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.284 · Cited by 539
Self-citationBalachandran, V. P., Cavnar, M. J., Zeng, S., Bamboat, Z. M., Ocuin, L. M., Obaid, H., Sorenson, E. C., Popow, R., Ariyan, C., Rossi, F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2438 · Cited by 521
Metz, R., DuHadaway, J. B., Kamasani, U., Laury-Kleintop, L., Muller, A. J., & Prendergast, G. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1872 · Cited by 467
Self-citationSinha, P., Clements, V. K., & Ostrand-Rosenberg, S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.636 · Cited by 466
Self-citationOncogenic Ras-induced secretion of IL6 is required for tumorigenesis
Ancrile, B., Lim, K.-H., & Counter, C. M. (2007) · Genes & Development · doi:10.1101/gad.1549407 · Cited by 422
Sharma, M. D., Hou, D.-Y., Liu, Y., Koni, P. A., Metz, R., Chandler, P., Mellor, A. L., He, Y., & Munn, D. H. (2009) · Blood · doi:10.1182/blood-2008-12-195354 · Cited by 409
Self-citationImmune escape as a fundamental trait of cancer: focus on IDO
Prendergast, G. C. (2008) · Oncogene · doi:10.1038/onc.2008.35 · Cited by 325
Self-citationVascular Endothelial Growth Factor and Its Relationship to Inflammatory Mediators
Angelo, L. S., & Kurzrock, R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2416 · Cited by 295
Induction of pulmonary indoleamine 2,3-dioxygenase by interferon.
Yoshida, R., Imanishi, J., Oku, T., Kishida, T., & Hayaishi, O. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.1.129 · Cited by 292
Song, X., Krelin, Y., Dvorkin, T., Bjorkdahl, O., Segal, S., Dinarello, C. A., Voronov, E., & Apte, R. N. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.12.8200 · Cited by 290
Baban, B., Chandler, P., McCool, D., Marshall, B., Munn, D. H., & Mellor, A. L. (2004) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2003.11.003 · Cited by 274
K-ras activation generates an inflammatory response in lung tumors
Ji, H., Houghton, A. M., Mariani, T. J., Perera, S., Kim, C. B., Padera, R., Tonon, G., McNamara, K., Marconcini, L. A., Hezel, A., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209237 · Cited by 271
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Muller, A. J., & Scherle, P. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1929 · Cited by 262
Self-citationKoblish, H. K., Hansbury, M. J., Bowman, K. J., Yang, G., Neilan, C. L., Haley, P. J., Burn, T. C., Waeltz, P., Sparks, R. B., Yue, E. W., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0628 · Cited by 242
Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma.
Ozaki, Y., Edelstein, M. P., & Duch, D. S. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.4.1242 · Cited by 240
Muller, A. J., Sharma, M. D., Chandler, P. R., DuHadaway, J. B., Everhart, M. E., Johnson, B. A., Kahler, D. J., Pihkala, J., Soler, A. P., Munn, D. H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806173105 · Cited by 240
Self-citationInduction of indoleamine 2,3-dioxygenase in mouse lung during virus infection.
Yoshida, R., Urade, Y., Tokuda, M., & Hayaishi, O. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.8.4084 · Cited by 211
Orabona, C., Pallotta, M. T., Volpi, C., Fallarino, F., Vacca, C., Bianchi, R., Belladonna, M. L., Fioretti, M. C., Grohmann, U., & Puccetti, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810278105 · Cited by 204
Banerjee, T., DuHadaway, J. B., Gaspari, P., Sutanto-Ward, E., Munn, D. H., Mellor, A. L., Malachowski, W. P., Prendergast, G. C., & Muller, A. J. (2008) · Oncogene · doi:10.1038/sj.onc.1210939 · Cited by 175
Self-citationKumar, S., Malachowski, W. P., DuHadaway, J. B., LaLonde, J. M., Carroll, P. J., Jaller, D., Metz, R., Prendergast, G. C., & Muller, A. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7014155 · Cited by 169
Self-citationFasbender, A., Lee, J. H., Walters, R. W., Moninger, T. O., Zabner, J., & Welsh, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2732 · Cited by 158
Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
DeMichele, A. M., Martin, A.-M., Mick, R., Gor, P. P., Wray, L., Klein-Cabral, M., Athanasiadis, G., Colligan, T., Stadtmauer, E. A., & Weber, B. (2003) · PubMed · Cited by 155
Ostrand‐Rosenberg, S., Clements, V. K., Terabe, M., Park, J. M., Berzofsky, J. A., & Dissanayake, S. K. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5796 · Cited by 117
Self-citationHu, H.-M., Tian, Q., Baer, M., Spooner, C. J., Williams, S. C., Johnson, P. F., & Schwartz, R. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m910269199 · Cited by 93
Orabona, C., Belladonna, M. L., Vacca, C., Bianchi, R., Fallarino, F., Volpi, C., Gizzi, S., Fioretti, M. C., Grohmann, U., & Puccetti, P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.6582 · Cited by 88
Local Expression of Indoleamine 2,3-Dioxygenase Protects Engraftment of Xenogeneic Skin Substitute
Li, Y., Tredget, E. E., Ghaffari, A., Lin, X., Kilani, R. T., & Ghahary, A. (2005) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700022 · Cited by 87
Interleukin 6, but Not T Helper 2 Cytokines, Promotes Lung Carcinogenesis
Ochoa, C. E., Mirabolfathinejad, S. G., Ruiz, V. A., Evans, S. E., Gagea, M., Evans, C. M., Dickey, B. F., & Moghaddam, S. J. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0180 · Cited by 85
Shirey, K. A., Jung, J., Maeder, G. S., & Carlin, J. M. (2006) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2006.26.53 · Cited by 80
Peek, R. M., Mohla, S., & DuBois, R. N. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1777 · Cited by 75
Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate
Muller, A. J., DuHadaway, J. B., Jaller, D., Curtis, P. J., Metz, R. A., & Prendergast, G. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3613 · Cited by 65
Self-citationSeow, A., Ng, D. P.-K., Choo, S., Eng, P., Poh, W., Teh, M., & Wang, Y.-T. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi309 · Cited by 57
Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion
Muller, A. J., DuHadaway, J. B., Chang, M. Y., Ramalingam, A., Sutanto‐Ward, E., Boulden, J., Soler, A. P., Mandik‐Nayak, L., Gilmour, S. K., & Prendergast, G. C. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0891-4 · Cited by 57
Self-citationSaga (2010) · International Journal of Oncology · doi:10.3892/ijo_00000830 · Cited by 56
Nonaka, H., Saga, Y., Fujiwara, H., Akimoto, H., Yamada, A., Kagawa, S., Takei, Y., 町田, 静., Takikawa, O., & Suzuki, M. (2011) · PubMed · Cited by 50
Haines, B. B., Bettano, K. A., Chénard, M., Sevilla, R. S., Ware, C. M., Angagaw, M. H., Winkelmann, C. T., Tong, C., Reilly, J. F., Sur, C., et al. (2009) · Neoplasia · doi:10.1593/neo.81030 · Cited by 47
Kita, H., Shiraishi, Y., Watanabe, K., Suda, K., Ohtsuka, K., Koshiishi, Y., & Goya, T. (2011) · Annals of Thoracic and Cardiovascular Surgery · doi:10.5761/atcs.oa.10.01627 · Cited by 38
Metz, R. A., DuHadaway, J. B., Rust, S., Munn, D. H., Muller, A. J., Mautino, M. R., & Prendergast, G. C. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0185 · Cited by 32
Self-citationMuller, A., Mandik-Nayak, L., & Prendergast, G. (2010) · Immunotherapy · doi:10.2217/imt.10.22 · Cited by 26
Self-citation
Cited by
T cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
Veglia, F., Sanseviero, E., & Gabrilovich, D. I. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00490-y · Cited by 1,940
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,546
Pitt, J. M., Marabelle, A., Eggermont, A., Soria, J.-C., Kroemer, G., & Zitvogel, L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw168 · Cited by 1,338
Metadata
- Authors
- Smith, C., Chang, M. Y., Parker, K. H., Beury, D. W., DuHadaway, J. B., Flick, H. E., Boulden, J., Sutanto-Ward, E., Soler, A. P., Laury-Kleintop, L. D., Mandik-Nayak, L., Metz, R., Ostrand-Rosenberg, S., Prendergast, G. C., & Muller, A. J.
- Venue
- Cancer Discovery
- Published
- 2012-08-01
- Volume
- 2
- Issue
- 8
- Pages
- 722-735
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2148801612
- Cited by
- 322
- References
- 56
- FWCI
- 9.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.